咪唑斯叮联合白芍总苷治疗慢性荨麻疹

Efficacy Observation of Treatment of Mizolastine Combined with Total Glucosides of Paeony for Chronic Urticaria

目的:探讨咪唑斯汀联合白芍总苷治疗慢性荨麻疹的临床疗效及安全性分析,从而指导临床进一步治疗。方法:84例慢性荨麻疹患者,随机将其分为对照组(10 mg咪唑斯汀,每晚1次,治疗4周)和观察组(在对照组治疗基础上,加用600 mg白芍总苷胶囊,每日2次,治疗4周),每组各42例,根据症状积分下降指数(SSRI),对两组临床疗效、复发率、不良反应,以及血清Ig E。结果:与对照组相比,观察组治疗有效率明显提高(90.5%vs 71.4%),P<0.05;观察组复发率显著降低(42.9%vs 71.4%),P<0.05;观察组治疗后SSRI评分明显降低(0.7±0.2 vs 1.3±0.4)分,P<0.05;与对照组相比,观察组治疗后血清Ig E水平明显降低(82.5±13.6 vs 102.9±14.3)U·m L-1,P<0.05。治疗期间两组均没有明显不良反应。结论:咪唑斯汀联合白芍总苷治疗慢性荨麻疹的疗效显著、安全性高,值得临床推广。

Objective： To study the clinical efficacy and safety of the treatment of mizolastine combined with total glucosides of paeony for chronic urticaria, and to provide guidance for the future clinical treatment. Method： Eighty-four patients with chronic urticaria were randomized into the control group （10 mg mizolastine, once evening for 4 weeks） and the observation group （based on the control group, added 600 mg total glucosides of paeony capsules, twice daily for 4 weeks） of 42 patients per group. The clinical efficacy, recurrence rate and adverse reactions in the two groups were observed and compared according to the symptom score decreased index （SSRI）. Result： Compared with the control group, the effective rate was significantly increased （90.5% vs 71.4%, P〈0.05）, the recurrence rate was obviously reduced （42.9% vs 71.4%, P〈0.05）, the SSRI scores were significantly decreased after treatment （0.7±0.2 vs 1.3±0.4, P〈0.05）, the serum IgE levels were significantly reduced after treatment[（82.5±13.6） vs （102.9±14.3） U·mL^-1, P〈0.05] in the observation group. There were no obvious adverse reactions in the two groups during the treatment period. Conclusion： The treatment of mizolastine combined with total glucosides of paeony has significant efficacy and high safety for chronic urticaria, which is worthy of clinical promotion.